09 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/updated-data-for-nuvalents-alk-selective-inhibitor-nvl-655-and-ros1-selective-inhibitor-zidesamtinib-continue-to-support-potential-best-in-class-profiles-302241297.html
16 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nuvalent-to-present-updated-data-for-ros1-selective-inhibitor-zidesamtinib-and-alk-selective-inhibitor-nvl-655-at-the-esmo-congress-2024-302197499.html
08 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nuvalent-presents-new-preclinical-data-supporting-profiles-of-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024-302110869.html
05 Mar 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-on-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024-302080625.html